Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 36 No. 1 The Psychopharmacology of...
GENERAL PSYCHOPHARMACOLOGY

The Psychopharmacology of Fibromyalgia: A Drug Development Perspective

Psychopharmacology Bulletin 36(1) :165-213 , 2002/01/15

Abstract

The fibromyalgia syndrome (FMS) is the most frequent cause of chronic widespread pain. In this review, we summarize the state of the art on the syndrome and its pathophysiology, with an emphasis on identifying bases for the development of novel therapies. Toward this end, the anatomy and physiology of pain pathways are summarized, followed by a review of the altered biology of pain processing, neurotransmitter function, and neuroendocrine systems in FMS. The categories of drugs currently employed to treat the disorder are detailed, along with a critical review of the literature supporting such use. Throughout the article, FMS is compared with and related to both major depressive disorder and neuropathic pain, conditions that may share some common biological processes with FMS but for which new drug discovery efforts are significantly more active due to the more established nature of these diagnoses. Psychopharmacology Bulletin. 2002;36(1):165-213

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Jay D. Kranzler, MD, PhD, Judith F. Gendreau, MD, and Srinivas G. Rao, MD, PhD. The Psychopharmacology of Fibromyalgia: A Drug Development Perspective. Psychopharmacology Bulletin. 2002/01/15; 36(1):165-213.